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Background: Measures to protect healthcare workers where there is risk of injury or infection from medical sharps
became mandatory in the European Union (EU) from May 2013. Our research objective was to estimate the net
budget impact of introducing safety-engineered devices (SEDs) for prevention of needlestick injuries (NSIs) in a
Belgian hospital.
Methods: A 5-year incidence-based budget impact model was developed from the hospital inpatient perspective,
comparing costs and outcomes with SEDs and prior-used conventional (non-safety) devices. The model accounts
for device acquisition costs and costs of NSI management in 4 areas of application where SEDs are currently used:
blood collection, infusion, injection and diabetes insulin administration. Model input data were sourced from the
Institut National d’Assurance Maladie-Invalidité, published studies, clinical guidelines and market research. Costs are
discounted at 3%.
Results: For a 420-bed hospital, 100% substitution of conventional devices by SEDs is estimated to decrease the
cumulative 5-year incidence of NSIs from 310 to 75, and those associated with exposure to blood-borne viral
diseases from 60 to 15. Cost savings from managing fewer NSIs more than offset increased device acquisition costs,
yielding estimated 5-year overall savings of €51,710. The direction of these results is robust to a range of sensitivity
and model scenario analyses. The model was most sensitive to variation in the acquisition costs of SEDs, rates of
NSI associated with conventional devices, and the acquisition costs of conventional devices.
Conclusions: NSIs are a significant potential risk with the use of sharp devices. The incidence of NSIs and the costs
associated with their management can be reduced through the adoption of safer work practices, including
investment in SEDs. For a Belgian hospital, the budget impact model reports that the incremental acquisition costs
of SEDs are offset by the savings from fewer NSIs. The availability of more robust data for NSI reduction rates, and
broadening the scope of the model to include ancillary measures for hospital conversion to SED usage, outpatient
and paramedic device use, and transmission of other blood-borne diseases, would strengthen the model.
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The burden of needlestick injuries
Needlestick injuries (NSIs) are one of the most common
and serious risks to European healthcare workers. Such
injuries occur before, during and after sharp device use,
and affect both direct patient care staff and ancillary
staff, such as sanitation workers [1]. Data from the
United States (US) EPINet registry show that 34% of
NSIs reported to it are experienced by staff other than
the user of the sharp [2].* Correspondence: Lewis.Ruff@medaxial.com
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reproduction in any medium, provided the orOver 1 million NSIs are estimated to occur in the
European Union (EU) each year [3] and true injury rates
may be far higher due to under-reporting, which is esti-
mated to occur in 29–61% of cases [4]. Reasons for
under-reporting include: a presumption that the risk of
disease transmission is low; a lack of knowledge of sys-
tems for, or the necessity of, reporting NSIs; and report-
ing systems that are cumbersome or unclear.
The main risk following an NSI is infection with a
blood-borne virus [5]. This risk is exacerbated by the
heightened prevalence of these viral infections in hos-
pital patients compared to the general population –al Ltd. This is an open access article distributed under the terms of the Creative
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human immunodeficiency virus (HIV), as demonstrated
by Wicker et al. [6].
NSIs represent a significant clinical and economic bur-
den to healthcare systems and society [7]. The economic
burden of NSIs facing healthcare employers and insurers
was shown in a costing statement published by NHS
Scotland [8] to stem from costs such as:
 Testing for infection in the injured worker and, if
known, the patient on whom the sharp had been used.
 Post-exposure prophylaxis (PEP) to prevent or
manage potential blood-borne virus transmission.
 Short- and long-term treatment of chronic blood-borne
viral infections that are transmitted to injured workers.
 Staff absence and replacement.
 Counselling for injured workers.
 Legal consequences (e.g. litigation and compensation
claims).
Estimates of the economic burden of NSIs are consider-
able but vary across countries and studies due to the dif-
ferent study methodologies used. For example, Saia et al.
reported annual costs due to NSIs of between €4.6 million
and €30 million in Germany, $6.1 million in France (con-
sidering nurses alone), €7 million in Italy (not considering
long-term treatment, compensation or indirect costs), be-
tween €6 million and €7 million in Spain, and between £4
million and £300 million in England and Wales [9].
NSIs may also have a detrimental impact on healthcare
workers’ psychological well-being or quality of life. For
instance, in one survey of workers exposed to blood or
body fluids, 53% reported symptoms of anxiety and 18%
symptoms of depression [10]. Many respondents re-
ported that they were worried for up to a year after the
incident even when the source patient was confirmed
negative of infection. In a Korean survey conducted by
Sohn et al. [11], 370 healthcare workers’ self-reported
levels of anxiety and depression were elevated after be-
coming injured and stress levels increased in those who
were not vaccinated against hepatitis B.
In a US survey of 400 acute care nurses [12], 110 had
experienced an NSI in the previous 12 months. Of these,
42% reported that they were anxious, depressed or
stressed during the two-week period following injury and
60% reported feeling more afraid of needled devices than
before. In the 12-month period, these NSIs generated 19
counselling visits and 61 days of work absence due to
emotional distress and anxiety alone. The same study re-
ported that an additional 10 days of work were missed as a
result of seeking and receiving medical attention.
Fear of transmission of chronic blood-borne virus in-
fection is particularly impactful on a healthcare worker’s
well-being. In a survey of accident and emergencydoctors, over 70% indicated that their worst fear was an
NSI associated with care of an HIV-infected patient [13].
In another study among doctors, focused specifically on
the impact of HIV infection risk on outlook and beha-
viour, most stress was reported by those who had previ-
ously experienced an NSI [13].
The European directive
In recognition of the burden of sharps injuries including
NSIs, an EU Directive on the prevention of sharps injuries
(Council Directive 2010/32/EU) was adopted into European
law in May 2010 [14]. The Directive calls for the elimination
of risk to the maximum degree possible and, beginning with
mandatory risk assessment, it recommends adherence to a
range of measures to eliminate risk where it exists to pre-
vent injury and protect healthcare workers, including:
 Implementing safe procedures for using and
disposing of sharps and contaminated waste.
 Eliminating unnecessary use of sharps, including
provision of devices with safety-engineered protection
mechanisms.
 Implementing safe systems of work including
training and health surveillance procedures.
 Provision of personal protective equipment.
 Vaccination.
The deadline for compliance to the directive for EU
member states was 11th May 2013.
Safety-engineered devices (SEDs)
SEDs are engineered with automatic or manually-
activated shields or retraction mechanisms designed to
protect the device user from exposure to the sharp by
covering the sharp immediately following use. Typically,
the safety mechanism is either automatic or engineered
for rapid and intuitive activation, which for some devices
is single-handed for convenience and ease of use.
A French, multicentre, prospective survey conducted
across 102 medical units to explore the effect of the
introduction of SEDs when conducting sharp procedures
found that, in combination with training and safer work-
ing practices, there was a 75% reduction in the incidence
of NSIs [15].
The addition of safety features increases the acquisi-
tion cost of these devices relative to conventional de-
vices. Accordingly, we developed a budget impact model
to understand the potential overall economic impact of
introducing SEDs in Belgian hospitals.
Methods
Model design
An incidence-based, deterministic budget impact model
with a five-year time horizon was developed from the
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patient setting. Pertinent direct and indirect costs were
considered.
The model was developed in accordance with recom-
mendations published by the International Society for
Pharmacoeconomics and Outcomes Research (ISPOR)
Task Force on Good Research Practices [16], as far as pos-
sible. It takes into account device acquisition costs and
other direct and indirect costs associated with NSIs in four




 Diabetes insulin administration.
Current and revised care pathways were compared. In
the base case scenario it was assumed that no SEDs are
used in the current care pathway and that SED use is
100% in the revised care pathway. All model inputs were
sourced from a targeted literature review. Belgian data
sources were used where possible for model input data;
otherwise the next most suitable sources were used.
Parameters
Devices and incidence of NSIs
The average number of relevant devices used in a Belgian
hospital was based on an estimate of the average number
of beds per hospital – 420 [17] – and the annual number
of devices used per bed, based on market research data
from Becton, Dickinson and Company, in addition to pro-
curement data for blood collection devices used per in-
patient bed reported by NHS Scotland [8] (it was assumed
that each device is a single-use device and not reused).
NSI rates associated with use of conventional devices and
the expected reduction in NSI rates associated with SEDs
were based on Lamontagne et al. [15] and Pellisier et al.
[18]. These data are shown in Table 1.
Transmission of blood-borne viruses
The risk of contracting hepatitis B, hepatitis C and HIV
from an NSI was calculated based on:Table 1 Estimated annual number, cost and NSI rate associat







Infusion therapy 120 0.400
Diabetes insulin administration 50 [8] 0.095
Blood collection 193 0.170
*It was assumed that arterial and venous blood collection procedures result in the s
**It was assumed that the reduction in NSIs after the introduction of 2nd generation
injection SEDs.
***It was assumed that safety-engineered arterial and venous blood collection devi The prevalence of these diseases in a hospital
population (shown in Table 2), derived from a study
of reported exposures to blood between 2003 and
2010 in a major academic medical centre [19].
 A disease transmission rate of 30%, 1.8% and 0.31%,
respectively [20,21], (shown in Table 2).
 The proportion of healthcare workers vaccinated against
hepatitis B – 89%, based on a published European range
of 85–93% reported by De Schryver et al. [22].
 Prior effectiveness of hepatitis B vaccination deemed
to be 90%, based on a reported range of 85–95%
effectiveness in preventing hepatitis B infection [23].
The model also factors in the percentage of cases
where the source of an NSI is unknown (23%) [24].
Cases such as these, as well as those cases where the
source patient is known to carry one or more of the
three considered blood-borne viral infections, are treated
as high-risk NSIs and make up 39% of the NSIs that
occur. Low-risk NSIs – those where the source patient is
identified and confirmed as uninfected with HIV, hepa-
titis B or hepatitis C – make up the remaining 61%.
Costs
The direct and indirect costs of managing an NSI were
assumed to be the same across all clinical applications.
It was assumed that the use of SEDs only affects the
overall number of NSIs. The proportions of high- and
low-risk NSIs were assumed to be the same with the
usage of both SEDs and conventional devices.
Belgian unit costs were taken from the Institut National
d’Assurance Maladie-Invalidité (INAMI) database [25,26],
where possible.
The direct cost parameters included in the model are
outlined in Table 3.
Costs associated with testing for blood-borne viral infec-
tions after an NSI were based on a regimen determined
from clinical guidelines [27-29], peer-reviewed studies
[6,30] and INAMI costs [26]. The costs of staff time re-
quired for administrative procedures following an NSI
were based on resource use estimates from a Belgian











0.046 10.8 [15] 1.5
0.600 26.0 [15] 8.8
0.315 23.5 [18] 3.3**
0.270 23.4* [15] 7.0***
ame percentage of NSIs.
safety-engineered diabetes care devices is the same as that achieved by
ces achieve the same reduction.
Table 2 Estimated prevalence and transmission rates of
blood-borne viruses
Hepatitis B Hepatitis C HIV
Prevalence in a hospital
population [19]
4.9% 7.9% 9.0%
Transmission rate 30% [20] 1.8% [20,21] 0.31% [20,21]
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model does not factor in costs associated with personnel
replacement.
Based on Belgian clinical guidelines [32,33], PEP for
hepatitis B and HIV was applied to victims of NSIs aris-
ing from a known and infected source or an unknown
source. Hepatitis B PEP consisted of a course of four
doses of hepatitis B recombinant vaccine for unvaccin-
ated workers and one dose for vaccinated workers,
whilst HIV PEP consisted of 28 days treatment with a
combination of lopinavir, ritonavir, emtricitabine and
tenofovir disoproxil. It was assumed that where the
source patient is known and infected, the average cost of
PEP with HIV and hepatitis B would be applied,
weighted by the prevalence of these blood-borne viruses
[19], and where the source patient is unknown the cost
of both hepatitis B and HIV PEP would also be applied.
Patients treated for:
 Hepatitis B receive either peginterferon, lamivudine,
adefovir dipivoxil or entecavir, as documented by the
United Kingdom (UK) National Institute for Health
and Care Excellence (NICE) [34].
 Hepatitis C receive combination therapy with
peginterferon alfa and ribavirin [35] for 48 weeks,
according to NICE guidance [36].
 HIV incur an annual treatment cost based on the
annual cost of antiretroviral therapy reported in the
UK for 2006 [37], converted to 2012 Euro [38],Table 3 Direct costs associated with NSIs
Direct costs of NSIs
Testing for blood-borne viruses [6,26-30] in:
NSI recipient – initial test €38.76
NSI recipient – follow-up test €58.52
Source patient (if known) €43.91
Cost of staffing and administration per NSI [26,31] €68.81
Cost of PEP for hepatitis B and HIV [19,25,32,33] per:
NSI from a known and infected source €374.61
NSI from an unknown source €918.76
Cost of treatment of blood-borne viruses [19,25,34-38]: €2,377.44
Hepatitis B (year in which NSI occurred and per
subsequent year for three years)
Hepatitis C (year in which NSI occurred only) €16,127.76
HIV (year in which NSI occurred and per subsequent year) €16,999.83making the conservative assumption that all patients
remain asymptomatic in the first five years following
infection and receive monotherapy treatment.
INAMI drug costs were used for both PEP and treat-
ment of blood-borne viruses [25].
The overall direct cost per NSI is shown in Table 4.
The model includes indirect costs of NSIs, namely: coun-
selling NSI victims, staff absence and compensation. It was
assumed that all victims of NSIs would require at least an
initial counselling session, with recipients of high-risk NSIs
requiring a further three follow-up sessions [39], costed
using INAMI unit cost data [26]. The cost of staff absences
was based on a report by the Netherlands National Hepa-
titis Centre [40], and productivity loss costs were derived
from Belgian national statistics [41]. It was conservatively
assumed that no low-risk NSIs result in compensation
claims. For high-risk NSIs, it was assumed that 4% result
in compensation [12]. The estimated compensation cost
per NSI was based on UK experience [42-44] converted to
2012 Euro using historical exchange rates [38].
Average indirect costs incurred per NSI are shown in
Table 5.
Costs were discounted at 3%, in line with Belgian
guidelines for pharmacoeconomic evaluation [45]. The
model conservatively assumes that only costs (device
costs and direct and indirect costs relating to NSIs) in-
curred within the model time horizon are included. This
may understate the true cost of chronic blood-borne dis-
eases, such as those for HIV infection, where ongoing
lifetime treatment is required.
Sensitivity analysis
One-way sensitivity analyses were performed by varying
the following model parameters:
 Number of hospital beds (±20%).
 Number of devices used (±20%).Table 4 Average direct costs incurred per low- and
high-risk NSI
NSI risk category Low High
Source patient Known Unknown
Infection status Uninfected Infected Uninfected Infected
Testing €141.20 €141.20 €85.09 €85.09
Staff and administration €68.81 €68.81 €68.81 €68.81
PEP – €374.61 €918.76 €918.76
Disease treatment – €142.99 – €142.99
Total direct cost per NSI €210.01 €727.61 €1,072.66 €1,215.65
Relative incidence
within risk category
100% 33% 58% 10%
Total direct cost per NSI,
by risk category
€210.01 €950.34
Table 5 Average indirect costs incurred per low- and
high-risk NSI
Risk category Low High
Counselling [26,39] €40.27 €238.45
Staff absence [40,41] €22.95 €229.51
Compensation and litigation [12,38,42-44] – €376.26*
Total indirect cost per NSI €63.22 €844.22
*Estimated based on an average of the costs reported by three English
compensation cases involving a healthcare worker experiencing an NSI
[42-44], weighted by the relative proportion of high-risk NSIs resulting in sero-
conversion to either hepatitis B, hepatitis C or HIV from an infected source,
and converted to 2012 Euro [38].
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 Cost per SED (±20%).
 Rate of NSIs with conventional devices (±20%).
 Reduction in NSIs with SEDs (±20%).
 Prevalence of hepatitis B, hepatitis C and HIV (±20%).
 Rate of transmission of hepatitis B, hepatitis C and
HIV (±20%).
 Cost of HIV treatment – the upper and lower
bounds (€16,999.83 and €40,336.42) corresponding
to the lowest and highest estimated annual costs of
retroviral therapy for asymptomatic patients in the
UK for 2006 [37], converted to 2012 Euro [38].
 The proportion of workers vaccinated against
hepatitis B set to 85% and 93% – the upper and
lower bounds reported by De Schryver et al. [22].
 Direct cost per NSI (±20%).
 Indirect cost per NSI (±20%).
In addition, the following scenarios were modelled:
 All compensation and litigation costs excluded from
the model.



























Figure 1 Estimated incidence of events over the model’s five-year tim
worker exposures to blood-borne diseases.Results
Base case scenario
We estimated that a 420-bed hospital will conduct
384,720 sharps procedures per annum. Over five years,
the modelled cost of conducting these procedures using
conventional devices was estimated to be €443,120, of
which €258,270 (58%) was spent managing 310 NSIs.
If all procedures were instead conducted using SEDs, the
model estimated that the number of NSIs would be reduced
to 75, avoiding 235 NSIs and 45 exposures to blood-borne
viruses, as shown in Figure 1. Total costs with SEDs were
estimated to be €391,450, representing an overall cost saving
of €51,710 or 12%. A €142,640 increase in device acquisition
costs is offset by a €194,350 reduction in NSI management
costs. These overall cost savings are primarily attributable to
a reduction in the cost of PEP, as shown in Figure 2.
A threshold analysis estimated that SEDs would still
confer cost savings if the average NSI rate reduction was
as low as 32% across the four clinical applications.
Sensitivity analysis results
The results of the one-way sensitivity analyses are shown
in Figure 3. The model was most sensitive to variation in
the acquisition costs and rates of NSIs associated with
both SEDs and conventional devices. For changes in the
acquisition costs of SEDs, the range between the upper
and lower bounds of net hospital budget impact was
€103,420. The model was relatively insensitive to changes
in variables related to blood-borne viruses.
The results of scenario analyses are presented in Figure 4.
Reducing the uptake of SEDs resulted in lower overall cost
savings. The exclusion of compensation and litigation costs
had a larger effect, with overall cost savings being reduced
to €19,760.
Discussion
The model demonstrates that the healthcare costs asso-










































Figure 2 Breakdown of NSI management cost savings, by cost category.
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tected by investment in SEDs, the acquisition costs of
which may be offset by the savings from fewer NSIs.
The model suggests that a hospital with 420 beds
would expect to see a reduction of over 70% in the num-
ber of NSIs it would face when using conventional sharp-€1
-
-€180,00
Variation in transmission of hepatitis B ±20%
Upper and lower limits of hepatitis B vaccination
Variation in transmission of HIV ±20%
Variation in transmission of hepatitis C ±20%
Variation in transmission of all viruses ±20%
Upper and lower limits of HIV treatment cost
Variation in prevalence of hepatitis B ±20%
Variation in prevalence of hepatitis C ±20%
Variation in prevalence of HIV ±20%
Hospital beds ±20%
Devices used ±20%
Variation in prevalence of all viruses ±20%
NSI indirect cost estimates ±20%
NSI direct cost estimates ±20%
NSI rates with SED ±20%
All device acquisition costs ±20%
Conventional device acquisition costs ±20%
NSI rates with conventional devices ±20%
SED acquisition costs ±20%
Figure 3 Results of one-way sensitivity analyses.devices, from an estimated 310 NSIs over five years to
75 NSIs following introduction of SEDs. This would lead
to 45 fewer exposures (over five years) to HIV, hepatitis
B and hepatitis C viruses. The model predicts an annual
NSI rate of 16.1 per 100,000 procedures with conven-






















































costs excluded SED use 75% SED use 50%
Figure 4 Results of scenario analyses.
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French study conducted in the 1990–7 period which
observed pre-conversion NSI rates of 12.7 per 100,000
needles compared to 6.4 per 100,000 needles post-
conversion [46]. However, comparison is not straightfor-
ward. The period covered by this study suggests an older
generation of SEDs with different features and potential
for reductions in rates of NSI. No information is given
as to whether conversion to SEDs was 100% and there is
no information on the comprehensiveness of reporting
of NSIs. Regarding the latter, the study may be vulner-
able to under-reporting in 1990 during the period of
conventional device usage, and much fuller reporting in
1995–7 with other policy changes introduced concurrent
to the introduction of SEDs: healthcare worker educa-
tion and a change in French worker compensation
policy.
In May 2013, measures to prevent injuries, where
there is a risk of injury or infection from a medical
sharp, were legally mandated by the EU Directive [14].
In addition to the primary purpose of improving health-
care worker safety, the current model suggests that in-
vestment in safety devices carries economic benefits.
Extrapolating the estimated net cost savings of approxi-
mately €51,700 per 420-bed hospital over five years, and
assuming similar savings across all 141 general hospitals
in Belgium [17], the model results suggest an overall na-
tional budget saving of approximately €7,300,000 could
be achieved over five years. This estimate is broad and
does not take account of national variation in hospital
size, variation in usage of sharps devices across hospitals
or variation in the existing usage of SEDs. The market
place for sharps devices is also competitive with device
unit acquisition costs varying by time and place, so
budget impact analyses are both institution- and time-
specific.
Sensitivity analyses show that for all of the varied pa-
rameters, with the exception of acquisition costs for
SEDs, the model estimates overall hospital budget cost
savings. However, for some parameters, such as theacquisition costs for SEDs, rates of NSI associated with
conventional devices and the acquisition costs of con-
ventional devices, there is a wide range of uncertainty
about the magnitude of overall hospital budget impact.
Other analyses from the published literature also re-
port economic benefits from the implementation of
SEDs. A UK cost-benefit analysis of two alternative
European Commission strategies (legislative vs. non-
legislative) to protect healthcare workers, including the
use of SEDs, estimated annual net benefits of £1 million
to £5 million over 10 years in 2008 GBP [47]. A Swedish
analysis, using clinical and economic data from a sample
of 18 hospitals, estimated savings of €850,000 in 2007
Euro from introducing safety needles and syringes in all
Swedish hospitals [48]. However, the analysis excluded
productivity costs and costs of chronic infection ac-
quired from NSIs, and no account was made of any add-
itional costs for the purchase of SEDs.
Studies conducted in the US have shown similar
trends: in 2000, the US General Accounting Office
(GAO) concluded that switching to SEDs could avoid
139,000 NSIs and save up to $90 million over one year,
depending on the cost of SEDs relative to conventional
devices and the cost of post-exposure treatment [49].
NSIs also generate significant intangible costs in the
form of the anxiety and distress of injured healthcare
workers and their families. A survey of 116 recently-
injured healthcare workers found that they would be
willing to pay $850 to avoid an NSI – an amount which
increased to $1,270 when higher risk was factored in
(e.g. working with a difficult patient or a patient infected
with hepatitis B, hepatitis C or HIV) – and is within the
range of the direct cost of $500–$2,500 per NSI as ap-
proximated by the US GAO [49,50].
Although not directly comparable to the budget im-
pact analysis approach used in our study, European
cost-effectiveness analyses of introducing measures to
prevent NSIs have also been undertaken. In their study
of a 1,300-bed hospital in Spain, Armadans Gil et al.
[51] found that safety needles for implanted ports were
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such as compensation and counselling: the cost effect-
iveness of SEDs ranged from savings of €2.65 (for im-
planted ports) to costs of €13,564 (for short catheters)
per NSI avoided, in 2003 Euro. Roudot-Thoraval et al.
[46] reported that for a 1,050-bed hospital in France, a
combined intervention of healthcare worker education
and conversion to SEDs was associated with a 75% and
50% reduction in re-capping rates and NSIs over one
year, respectively, at a cost of $4,000 per injury avoided.
One area in which the model is limited is that survey
data are used to estimate the reduction in NSIs arising
from the use of SEDs [15,18], and underreporting of the
true number of NSIs may underestimate the true reduction
in NSIs expected with these devices. This underreporting
is likely to result in an underestimation of the cost savings
associated with switching from conventional devices to
SEDs, since fewer than the true number of healthcare
workers expected to incur direct and indirect costs associ-
ated with NSI management will be modelled. The scale of
this issue is highlighted by evidence that between 29–61%
of healthcare workers who experience an NSI do not re-
port it [52]. The model does not explicitly consider the cost
of other ancillary measures to convert a hospital from con-
ventional to SED usage – such measures might include risk
assessment, staff training, work practice redesign and con-
trols implementing safer usage and handling procedures,
provision of personal protective equipment and routine
worker vaccination against blood-borne diseases.
A further limitation of the model is that outpatient
and paramedic device use are not considered. Their in-
clusion would be expected to result in an increase in
both the incidence of NSIs, and therein the number of
NSIs avoided through conversion from conventional de-
vices to SEDs, thereby increasing both the potential clin-
ical and economic benefits estimated by the model. In
addition, infections from around 30 pathogens transmit-
table through NSIs [3], beyond the three blood-borne vi-
ruses considered, are not included in the model. Again,
the model is conservative in this limitation: an expansion
of the transmissible infections considered would widen
the scope of estimated benefits from the use of SEDs.
The robustness of the results could be improved if bet-
ter data sources were available for the model input vari-
ables. For example, observational study data on NSI
rates with conventional devices compared with SEDs
would be preferable to survey data. Similarly, the use of
Belgium-specific data would be preferable to using data
from other Northern European countries where Belgian
data are currently lacking, such as for the prevalence of
blood-borne viral diseases in hospital patients and com-
pensation costs.
Our study provides a current analysis: many published
studies of this nature are now relatively old; in arecently-conducted systematic review [53] two thirds of
identified studies were carried out before 2001. Our ana-
lysis is also comprehensive with respect to inclusion of
important pertinent costs and undertakes extensive sen-
sitivity and scenario analyses. In the existing published
literature, some relevant costs are often not taken into
account and uncertainty analysis is often lacking.Conclusion
Costs associated with NSIs are a significant and avoidable
cost of using sharps devices. This model suggests that
SEDs reduce the economic burden of managing NSIs,
which may partially or completely offset any increase in
device acquisition costs. Associated health and quality of
life benefits for healthcare workers from a reduction in
rates of NSI can be achieved alongside potential reduc-
tions in Belgian health system expenditures through con-
version to using safety-engineered sharps devices.Competing interests
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